SiBionics Explores Automated Insulin Delivery at EASD 2026 Conference
At the EASD 2026 conference, SiBionics presented new prospects for automated insulin delivery, linking continuous monitoring with future diabetes care.
Milan – Diabetes research is advancing as SiBionics presented new directions for automated insulin delivery at the European Association for the Study of Diabetes (EASD) 2026 annual meeting. The company held a presentation titled "See More, Act Sooner," which highlights the potential of continuous glucose monitoring to improve care for patients with diabetes.
SiBionics' presentation focused on how technology can enable earlier responses to changes in blood glucose levels. This approach aims to reduce the risk of diabetes complications and enhance patients' quality of life by offering more precise and proactive care. The presentation covered three key areas related to the integration of continuous monitoring and future treatment modalities.
The EASD 2026 conference brings together leading diabetes researchers and clinicians globally. The participation of companies like SiBionics underscores the rapid development in the field and the significance of new technological solutions for managing this chronic condition. The objective is to create a more seamless care experience where technology supports both patients and healthcare professionals in daily decision-making.